Margarida Maia, PhD,  science writer—

Myasthenia gravis (MG) may be more likely to begin manifesting in the summer, with the onset of symptoms more common in hotter weather, according to a new study by researchers in Italy. The team theorized that the increased incidence of MG may occur because temperatures at that time of…

The COVID-19 pandemic caused emotional challenges for many people with myasthenia gravis (MG) in Australia, but how well their disease was treated or how well  their symptoms were kept under control weren’t affected, a survey study finds. “As we continue to live with COVID-19, clinicians should consider its various…

Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and made daily life easier when used in addition to standard of care therapy over six months, but its clinical benefit was somewhat limited. These data from LUMINESCE (NCT04963270), a…

People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis, two autoimmune diseases of the thyroid gland, according to a study in China. Researchers also found a genetic link in the opposite direction, where being genetically predisposed to Graves’ disease…

Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases driven by immunoglobulin G (IgG) self-reactive antibodies, the company announced in a press release. According to the U.S.-based biotech, CYR212’s profile — as seen in preclinical data culled from…

Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…

The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and even higher for women and patients with very severe symptoms or coexisting conditions such as mental health problems or severe infections. A large portion of direct costs in all three…

Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing antibody, according to six-month data from an open-label clinical trial. The Phase 2/3 Vibrance-MG study…

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the skin, or subcutaneously, appears to be as effective as the intravenous treatment Vyvgart (efgartigimod alfa) at reducing IgG antibodies, including those that cause the disease. That’s according to data…

Soliris (eculizumab) effectively eased symptoms and reduced the need for other medications in adults with myasthenia gravis (MG) in a clinical practice setting, according to two-year data from an observational study called ELEVATE. Findings were reported in the study “United States clinical practice experience with eculizumab in…